Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, New York
- Most recent report
- 8-K, filed Nov 3, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 78003
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 23
News 8 of 62
Prospectuses and Registrations 8 of 19
- S-8 Registration statement for an employee plan May 5, 2026
- 424B5 Prospectus supplement for an offering Nov 20, 2025
- FWP Free writing prospectus Nov 19, 2025
- 424B3 Prospectus supplement for an offering Nov 18, 2025
- 424B5 Prospectus supplement for an offering May 15, 2025
- FWP Free writing prospectus May 14, 2025
- 424B3 Prospectus supplement for an offering May 13, 2025
- S-8 Registration statement for an employee plan May 9, 2024
Proxies 8 of 42
- DEFA14A Extra proxy material Mar 12, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 12, 2026
- DEFA14A Extra proxy material Apr 11, 2025
- DEFA14A Extra proxy material Apr 10, 2025
- DEFA14A Extra proxy material Apr 10, 2025
- DEFA14A Extra proxy material Apr 10, 2025
- DEFA14A Extra proxy material Apr 7, 2025
- PX14A6G Shareholder's own proxy material Mar 25, 2025
Ownership 8 of 818
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Oct 16, 2026
- SCHEDULE 13G Large holder reported a passive stake Oct 16, 2026
- 4 Insider reported a trade Oct 14, 2026
- 4 Insider reported a trade Oct 1, 2026
- 4 Insider reported a trade Sep 29, 2026
- 4 Insider reported a trade Sep 29, 2026
- 4 Insider reported a trade Sep 29, 2026
Other 8 of 36
- N-PX Record of how a fund voted its shares Aug 31, 2026
- 11-K Employee stock plan report Jun 16, 2026
- 11-K Employee stock plan report Jun 16, 2026
- ARS Annual report sent to shareholders Mar 12, 2026
- 11-K Employee stock plan report Jun 16, 2025
- 11-K Employee stock plan report Jun 16, 2025
- SD Conflict minerals disclosure May 30, 2025
- CERT Exchange certified a listing May 20, 2025
What to read: Sep 2026 10-Q
SECSift found 2 of 11 sections worth reading, with 0 positive, 11 notable, and 2 negative flags.
Financial Statements (Item 1)
Financial statements and notes with major asset impairments, restructuring, and acquisition details.Notable- $650M upfront payment to Innovent for in-licensing 12 early-stage cancer drugs, recorded as IPR&D expense in Q3 2026.
- Restructuring program costs now expected to total $7.3B, up from prior estimate, with $5.7B incurred through Q3 2026.
- Manufacturing optimization program expanded; new phase expected to cost ~$4.0B, 60% non-cash, through 2029.
Management's Discussion (Item 2)
Full MD&A with detailed segment results, cost programs, tariff deal, and product pipeline updates.Notable- Announced $1.0B additional cost savings from Realigning Our Cost Base program, expected 2027-2029.
- Patent exclusivity expiries expected to cause ~$1.1B revenue impact in 2026, accelerating thereafter.
- Pfizer reached binding tariff deal with U.S. government; Section 232 duty rate zeroed through Jan 2029.
- Announced next phase of Manufacturing Optimization Program targeting $1.5B savings from 2027-2029.
- Oxbryta permanently withdrawn from U.S. market after FDA determined no viable return path.
- Sigvotatug vedotin Phase 3 study failed primary endpoint of overall survival in NSCLC.
- No share repurchases in first nine months of 2026; remaining authorization $3.3B.
- Pfizer completed exit of 11.7% ViiV investment in March 2026, receiving $1.875B cash.
What changed: Sep 2026 vs. Jun 2026
About 5% of PFE's Sep 2026 10-Q is new information. 29 paragraphs were added, 177 changed, and 36 removed. Below are the most important lines SECSift identified.
Changed
- First-nine-months income before taxes fell to $5.9B from $9.2B, a $3.3B decrease, vs. prior six-month drop to $2.5B from $5.8B.
- First-nine-months total revenues rose to $46.1B from $45.0B, a $1.0B increase, vs. prior six-month increase of $1.1B to $29.5B.
- Third-quarter total revenues fell to $16.6B from $16.7B, a $71M drop, vs. prior Q2 increase of $381M to $15.0B.
- Third-quarter income before taxes rose to $3.4B from $3.3B, a $51M increase, vs. prior Q2 loss of $653M.
- Total revenues rose to $16,583M from $16,654M for Q3, and to $46,067M from $45,022M for nine months.
- Restructuring charges rose to $791M from $286M for Q3, and to $1,347M from $945M for nine months.
- Acquired IPR&D expenses fell to $669M from $1,390M for Q3, and to $822M from $1,401M for nine months.
- Other (income)/deductions––net fell to $288M from $517M for Q3, and rose to $4,866M from $2,210M for nine months.
- Net income fell to $3,242M from $3,541M for Q3, and to $5,681M from $9,419M for nine months.
- Shares surrendered for tax withholding fell to 54,453 from 134,760.
- Trustee open market purchases fell to 769 shares from 1,044 shares.
Everything here comes from Pfizer Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Nov 3, 2026, from the 10-Q for Sep 2026.